Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/466| Title: | Purple toes syndrome following stroke thrombolysis and warfarin therapy | Authors: | Mooney, T. Joseph, P. |
Issue Date: | 2014 | Source: | January 44, (1), 2014, p. 107-108 | Pages: | 107-108 | Journal: | Internal Medicine Journal | DOI: | http://dx.doi.org/10.1111/imj.12327 | Resources: | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=2014063008 | Keywords: | agedartery disease/dt [Drug Therapy];artery disease/si [Side Effect];artificial embolism;blood clot lysis;capillary;case report;cerebral artery disease/dt [Drug Therapy];cerebrovascular accident;cholesterol embolization syndrome/dt [Drug Therapy];cholesterol embolization syndrome/si [Side Effect];cyanosis;drug withdrawal;eosinophil count;female;fever;foot;foot pain;human;international normalized ratio;letter;leukocyte;leukocyte count;middle cerebral artery;myalgia;priority journal;pulse rate;purple toes syndrome/dt [Drug Therapy];rash;skin discoloration;skin necrosis/dt [Drug Therapy];skin necrosis/si [Side Effect];thrombocyte count;toe;very elderly;alteplase/dt [Drug Therapy];anticoagulant agent/po [Oral Drug Administration];C reactive protein/ec [Endogenous Compound];creatinine/ec [Endogenous Compound];enoxaparin/dt [Drug Therapy];enoxaparin/sc [Subcutaneous Drug Administration];hemoglobin/ec [Endogenous Compound];urea/ec [Endogenous Compound];warfarin/ae [Adverse Drug Reaction];warfarin/dt [Drug Therapy];warfarin/po [Oral Drug Administration] | Type: | Article |
| Appears in Sites: | Sunshine Coast HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.